Any current/future new fundraising through debt or equity?

No explicit mention of any current or future fundraising through debt or equity in the provided transcript. The company has discussed CAPEX plans totaling around ₹150 crores for the current year and ₹300-350 crores over the next 3 years focused on new plants, R&D facilities, and other projects. No specific details were given on how this CAPEX would be funded, such as through debt, equity, or internal accruals. Management did not indicate any plans for raising capital via equity or debt during the Q&A or closing remarks. Thus, based on the transcript, there is no disclosed fundraising plan thro

Any current/future capex/capital investment/strategic investment?

Current year CAPEX plan is ₹150 crores. Next 3 years planned investments are ₹300-350 crores. Investments include: - New herbicide plant (already started construction post-monsoon; ~₹100+ crores). - New state-of-the-art Research & Development (R&D) facility (expected completion by Q3 of next financial year). - New triazole fungicide plant for 3 major new molecules (construction to start after monsoon, ~1 year project duration). - Other miscellaneous projects contributing to ₹150 crores CAPEX this year. Additional CAPEX on CMO side will be done as new molecules come up after utilizing t

Future growth expectations in sales/revenue/volumes?

Enterprise business volume growth expected at 20% to 25% year-on-year driven by debottlenecking and new product introductions. CMO (Contract Manufacturing Organization) business growth forecasted at 6% to 8% for the current year, including contribution from the new herbicide plant. The new herbicide plant expected to add about ₹70-80 crores in sales turnover by the second year of operation with gradual ramp-up over three years. Introduction of 4 new CMO products this year, with some revenue starting in the current year and ramping up in subsequent years. Three additional new triazole f

Future growth expectations in earnings/operating earnings/profits/EPS?

Enterprise business volume growth expected at 20% to 25% year-on-year, driven by debottlenecking and herbicide plant output. Contract Manufacturing Organization (CMO) business projected to grow 6% to 8% in FY22, including contributions from the new herbicide plant. CMO growth to accelerate in coming years as inventory issues resolve and new projects commence. Introduction of 4 new CMO products and 1 enterprise product expected to drive revenue growth, with additional 3 new triazole fungicide molecules launching next year, supported by over ₹100 crore CAPEX. EBITDA margin targeted to im

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders in precise figures. However, it reflects ongoing strong demand for products, both domestic and international, with new contract manufacturing orders expected to grow moderately by 7-8% in the current fiscal year. The company is launching 4 new contract manufacturing (CMO) molecules and 1 enterprise sales product this year. The new herbicide plant and ongoing debottlenecking efforts are expected to add to volumes and revenues in the near term. The triazole fungicide plant construction is starting soo

Astec LifesciencQ1 FY22Fertilizers & Agrochemicals

Astec Lifescienc Q1 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.55Market Cap: ₹1.2K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Enterprise business volume growth expected at 20% to 25% year-on-year driven by debottlenecking and new product introductions.
CMO (Contract Manufacturing Organization) business growth forecasted at 6% to 8% for the current year, including contribution from the new herbicide plant.
The new herbicide plant expected to add about ₹70-80 crores in sales turnover by the second year of operation with gradual ramp-up over three years.
Introduction of 4 new CMO products this year, with some revenue starting in the current year and ramping up in subsequent years.
Three additional new triazole fungicide molecules expected to be commercialized next year with a CAPEX over ₹100 crores, targeting a significant market opportunity exceeding $1 billion.
Overall goal to increase CMO share from current ~20%, enhancing blended margins and driving accelerated growth in coming years.

Margin guidance

Category 3

Enterprise business volume growth expected at 20% to 25% year-on-year, driven by debottlenecking and herbicide plant output.
Contract Manufacturing Organization (CMO) business projected to grow 6% to 8% in FY22, including contributions from the new herbicide plant.
CMO growth to accelerate in coming years as inventory issues resolve and new projects commence.
Introduction of 4 new CMO products and 1 enterprise product expected to drive revenue growth, with additional 3 new triazole fungicide molecules launching next year, supported by over ₹100 crore CAPEX.
EBITDA margin targeted to improve incrementally (0.5% to 1%) as CMO share increases, with current CMO margins approximately 5% higher than enterprise sales.
Overall, management indicates moderate near-term growth with potential for faster expansion and improved profitability alongside capacity ramp-up and new product launches.

See what Astec Lifescienc management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or future fundraising through debt or equity in the provided transcript.
The company has discussed CAPEX plans totaling around ₹150 crores for the current year and ₹300-350 crores over the next 3 years focused on new plants, R&D facilities, and other projects.
No specific details were given on how this CAPEX would be funded, such as through debt, equity, or internal accruals.
Management did not indicate any plans for raising capital via equity or debt during the Q&A or closing remarks.
Thus, based on the transcript, there is no disclosed fundraising plan through debt or equity at this time.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in precise figures.
However, it reflects ongoing strong demand for products, both domestic and international, with new contract manufacturing orders expected to grow moderately by 7-8% in the current fiscal year.
The company is launching 4 new contract manufacturing (CMO) molecules and 1 enterprise sales product this year.
The new herbicide plant and ongoing debottlenecking efforts are expected to add to volumes and revenues in the near term.
The triazole fungicide plant construction is starting soon, with capacity building expected to drive growth in subsequent years.
Registration and regulatory processes for new molecules are underway, supporting future commercial production and order fulfillment.
Customers have a history with the company; long-term contracts (3 years rolling for CMO) indicate stable future order flow.

See what Astec Lifescienc management said on order book — free account, 30 seconds.

Capex plans

Yes

Current year CAPEX plan is ₹150 crores.
Next 3 years planned investments are ₹300-350 crores.
Investments include:
- New herbicide plant (already started construction post-monsoon; ~₹100+ crores).
- New state-of-the-art Research & Development (R&D) facility (expected completion by Q3 of next financial year).
- New triazole fungicide plant for 3 major new molecules (construction to start after monsoon, ~1 year project duration).
- Other miscellaneous projects contributing to ₹150 crores CAPEX this year.
Additional CAPEX on CMO side will be done as new molecules come up after utilizing the herbicide plant's spare capacity.
R&D expansion will increase molecule development capacity multifold.
Debottlenecking measures will drive volume growth in enterprise business with limited CAPEX.

Track Astec Lifescienc — get its next earnings analysis in your feed

How does Astec Lifescienc rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisAstec Lifescienc

Rev 2Mar 3

See where Astec Lifescienc sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Astec Lifescienc rank in Fertilizers & Agrochemicals?

Compare Astec Lifescienc against every Fertilizers & Agrochemicals company (Q1 FY22) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Astec Lifescienc's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Best Agrolife Ltd (Q2 FY27)
Revenue from operations for Q2 FY27 is ₹407 crore, reflecting a year-on-year decline of 21%. Key results statement takeaways from Best Agrolife Ltd's Q2 FY27 ea
Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear

Compare:vs Coromandel Inter vs F A C T vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →